06Mar/13

SymBio Announces Completion of Patient Enrollment of TREAKISYM® (SyB L … – Marketwire (press release)

SymBio Announces Completion of Patient Enrollment of TREAKISYM® (SyB L
Marketwire (press release)
This randomized trial is evaluating the combination of TREAKISYM® and rituximab versus R-CHOP 2. SymBio initiated this multicenter open-label Phase II trial as a line extension study for TREAKISYM® in November, 2011, in collaboration with Eisai.

and more »